Concepedia

Rajeev Ayyagari

RA

Statistics

Publications

32

Citations

1.1K

H-Index

17

Active since

2001

Affiliations

Analysis Group (United States)(Current)

Takeda (United States)

Teva Pharmaceuticals (United States)

University of Florida

Bayer (United States)

Rajeev Ayyagari is an author at Analysis Group (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Publications per year

2001–2023

32

Publications

32

Projecting Absolute Invasive Breast Cancer Risk in White Women With a Model That Includes Mammographic Density

Jinbo Chen, David Pee, Rajeev Ayyagari et al. · JNCI Journal of the National Cancer Institute · 2006 · 349 citations · Full text

Public Health, Biostatistics, Oncology +17

Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease

Daniel O. Claassen, Benjamin Carroll, Lisa M. De Boer et al. · Journal of Clinical Movement Disorders · 2017 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants

Meredith Mowitz, Rajeev Ayyagari, Wei Gao et al. · Frontiers in Pediatrics · 2019 · 68 citations · Full text

Medicine, Child Health, Pediatrics +17

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson et al. · The Journal of Headache and Pain · 2022 · 44 citations · Full text

Medicine, Neurology, Pharmacotherapy +16

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

Susan Halabi, Shan Jiang, Emi Terasawa et al. · The Journal of Urology · 2021 · 36 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 32